Skip to navigation Skip to content

News

Share

National MS Society Invests in Commercial Research by TG Therapeutics for Development of Oral TGR-1202 (umbralisib) to Treat Progressive MS

October 2, 2017

The National MS Society, through Fast Forward, will invest up to $254,452 to enable TG Therapeutics, Inc. to further the laboratory testing of TGR-1202 (umbralisib) as a potential oral treatment option for progressive MS. Renowned MS researcher Dr. Lawrence Steinman, of Stanford University, will lead the research team on this effort.
 
This investment stemmed from a request for proposals released by Fast Forward for projects focused on testing existing therapies or drug candidates to determine if they protect the nervous system from damage and/or repair damage, especially for the treatment of progressive MS. TGR-1202 is already being tested in people with blood cancers, so it is ready for testing in MS if the lab testing suggests potential benefit.
 
“We are hopeful that these proof of concept studies will support the rationale for further clinical development of TGR-1202 for progressive forms of MS, for which there are few treatment options,” said Mark Allegretta, PhD, Associate Vice President of Commercial Research at the Society. “This investment exemplifies our effort to identify clinic-ready candidates to expand the pipeline of therapies being tested for use in MS.”
 
TGR-1202 uses a novel mechanism to inhibit the production of immune B cells, which are known to be involved in MS disease activity. Another B-cell therapy, Ocrevus™ (ocrelizumab - Genentech, a member of the Roche Group), was recently approved for both primary progressive and relapsing MS.
 
Read More:
Read more about Fast Forward
Read more about research in progressive MS
 
Ocrevus is a Trademark of Genentech, a member of the Roche Group
 

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.

Share